Phase II Study of Afatinib in Patients With Tumors With Human Epidermal Growth Factor Receptor 2–Activating Mutations: Results From the National Cancer Institute–Molecular Analysis for Therapy Choice ...
Marker Sequential Test design. A potential concern with the subgroup-specific testing strategy is that it has lower power for therapies with moderate treatment effects that are similar across the ...
Q4 2025 Management View CEO Lishan Aklog reported that "our EsoGuard test volume in the fourth quarter was 3,664. That exceeds our target range that we've articulated regularly of approximately 2,500 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results